Skip to main content

Yaacov-Garbeli Dana's Form 4 filing

Entera Bio Ltd. (ENTX) · filed Nov 15, 2022

Accession no.
0001178913-22-004054
Filed
Nov 15, 2022
Trade date
Nov 11-14, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $30.0K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Yaacov-Garbeli DanaCIK 0001909822Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 11, 2022Ordinary Shares, par value NIS 0.0000769 per sharePPurchaseAcquired+30,000$0.52+$15,60030,000Indirect
Nov 14, 2022Ordinary Shares, par value NIS 0.0000769 per sharePPurchaseAcquired+26,580$0.54+$14,353.256,580Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)